AbbVie's 2026 forecast rose 1%. The share price rose 29%. Which number is right?

A 0.5% revenue beat, a $200 million raise and a record $298.74: what 30 October changed

AbbVie ($ABBV) reported revenue of $17.404 billion for the quarter to 30 September 2026, up 10.3%, and adjusted EPS of $3.82 against a $3.73 estimate. Skyrizi sold $5.776 billion (+22.9% operational) and Rinvoq $2.706 billion (+24.3%), while Humira fell 30.6% to $683 million. Full-year adjusted EPS guidance moved to $13.95-13.99 from $13.76-13.96, revenue to about $67.8 billion, and the fourth-quarter guide is $18.4 billion of sales and $3.83-3.87 of EPS.

Strip out the $0.69 of acquired R&D expense booked so far in 2026 and the underlying forecast is $14.66 at the midpoint. On 4 February 2026 the same figure was $14.47. The forecast has moved 1.3%. The share price went from $228.49 on 31 December 2025 to $294.90, a move of 29%, with a record close of $298.74 on 30 October 2026. About 28 of those 29 points are a higher price for the same dollar of profit, not more profit.

Why 50x earnings and 21x earnings describe the same $295 share

FPI's data show a P/E of 50.4x; on the Street's adjusted number the stock costs about 21x. Both are right, they just count different profits. In the nine months to 30 September 2026 GAAP EPS was $4.79 while adjusted EPS added up to $10.12. Two items explain most of the gap. Amortisation of acquired drug rights, mostly from the 2020 Allergan purchase, cost $7.377 billion pre-tax in 2025, or $3.50 per share. And a $4.734 billion nine-month charge for the rising value of royalties owed on Skyrizi - a liability that grows precisely because the best drug sells better than planned. Which E goes under the P/E ratio decides the verdict.

Amortisation is a paper cost; the royalties are not. The 10-Q shows nine-month operating cash flow of $14.871 billion and capital spending of $888 million, so free cash flow of about $13.98 billion after $2.717 billion of actual royalty payments. The quarterly dividend rises 5.2% to $1.82 from February 2027, which is $7.28 a year, or about $12.9 billion on 1.768 billion shares. That takes roughly 69% of free cash flow annualised at $18.6 billion. The dividend is covered by cash, not by GAAP profit, and that is why the FPI data flag it as uncovered.

The model's $216.84: a 3.61% cash yield, $70 billion of net debt and 24x EBITDA against peers at 14x

The FPI fair value is $216.84, and at $294.90 the stock trades 26.5% above it. Half the model is a DCF, which values the cash left after royalties, interest and investment. A free cash flow yield of 3.61% - the cash the business generates each year per dollar of market value - sits below the drug-maker median of 4.38%. The other 30% compares multiples: EV/EBITDA of 24.2x against an industry median of 14.3x, and price-to-sales of 7.9x against 3.7x. Price to free cash flow has gone from 10.9x at the end of 2021 to 27.7x now, while revenue grew at 1.8% a year over three years.

The balance sheet weighs on the cash half. Net debt is about $70.1 billion (cash of $10.774 billion against $80.9 billion of borrowings) after $17.974 billion of new bonds in nine months, partly to fund the $10.9 billion Apogee purchase closed on 3 September 2026, which costs $0.14 of EPS in 2026 and about $0.46 in 2027. For 2027, Vraylar's Medicare price falls to $770 from a $1,376 list on 1 January 2027, a 44% cut on a $4.2 billion drug, while Imbruvica is shrinking 26% a year and Humira 31%. At $216.84 the stock would be 15.5x the $13.97 guidance midpoint, close to a normal drug-maker multiple.

Street vs model: $315 against $216.84 is a 45% disagreement, and even the $235 low target beats the model by 8%

Wall Street counts 31 buy, 12 hold and 1 sell. The median target is $315, the mean $308.88, and the range runs from $235 to $340; 13 targets issued in the past month average $313.77. On 2 November 2026 RBC Capital lifted its target to $330 from $280 and Cantor Fitzgerald to $325 from $290, Canaccord Genuity moved to $338 and Guggenheim to $322, while Bernstein stayed at Market Perform with $275. BMO Capital set $315 on 4 November. At $294.90 the stock is 6.4% below the median target and 26.5% above the model.

The gap has a simple mechanism. $315 is 22.5x the $13.97 adjusted midpoint, right where the drug-maker median P/E of 21.8x sits, so the Street is paying an ordinary industry multiple for 11% revenue growth. The model's DCF leg sees what the P/E ignores: $2.717 billion of royalties in nine months, interest on $81 billion of debt and the 2027 price cuts. Consensus already expects $3.89 of fourth-quarter EPS, above the company's own $3.83-3.87 range, so the bar for 3 February 2027 is already set above the guide.

What moves $295 next: the 3 February 2027 guide, the $238 line and a Botox appeal

For the price to grow into $315, the 2027 guidance due on 3 February 2027 has to show double-digit EPS growth from the $14.66 base while absorbing the Vraylar cut and $0.46 of Apogee dilution, and the 29 October 2026 ruling that Botox was wrongly picked for Medicare negotiation has to survive a government appeal. For the price to drift towards $216.84, a 2027 guide at or below 2026's growth would be enough, with aesthetics still shrinking (Juvederm fell 11.8% in the quarter).

Three numbers to watch:

• Fourth-quarter revenue against the $18.4 billion guide, and adjusted operating margin against the 46.7% full-year target (it was 48.7% in the quarter to 30 September).
• The 200-day average at $238.22, 10% above fair value, and the 50-day at $270.78 - the levels where a pullback would test whether buyers still pay 21x adjusted earnings.
• An RSI of 66 at an all-time high: the stock is up 36% in a year against 13.1% for the S&P 500, on a forecast that moved 1%.